Select your country

Yann Brun to become new EVP, Head of Global Development, Portfolio, Regulatory and Business Development/Licensing of the STADA Group

  • 28/09/2020
  • Press Release
  • Successful Life Science Executive Yann Brun with strong track record in leading and developing teams to join October 1st 2020

  • Yann brings strong diversified experience from Marketing, Sales, Business Development and General Management and has worked within a broad range of geographies and cultures.

  • STADA CEO Peter Goldschmidt said: „I’m excited to have Yann on our global leadership team to bring STADA‘s already broad-based portfolio to the next level and secure our sustainable long-term growth. His entrepreneurial growth mindset will strengthen our position as a leading go-to-partner for developing and commercializing generics, consumer healthcare and specialty products.“

 

Bad Vilbel, September 28, 2020 – Yann Brun will strengthen the global STADA Leadership Team as Executive Vice President, Head of Global Development, Portfolio, Regulatory and Business Development/Licensing of the STADA Group. He succeeds Dr. Robert Knerr on October 1st, who will pursue new opportunities outside of STADA. The life science executive Brun is experienced in leading and developing teams and portfolios across geographies and cultures. He holds a Master of Business from IAE Lyon, School of Management.

„I’m excited to have Yann on our global leadership team to bring STADA‘s already broad-based portfolio to the next level and secure our sustainable long-term growth. His entrepreneurial growth mind-set will strengthen our position as a leading go-to-partner for developing and commercializing generics, consumer healthcare and specialty products”, stated STADA CEO Peter Goldschmidt. “I would like to use this opportunity to express my sincere thanks to Robert Knerr. For around 10 years, he has played a leading role in developing STADA’s product portfolio. I wish him all the best for his personal and professional future.”

Yann started his pharma career in 1996 and worked in different Sales and Marketing positions for Founier Pharma in France, Romania, Spain and Poland. Between 2006 and 2010 he was General Manager of Solvay Czech Republic and Slovakia before joining Abbott where he was responsible for the Portfolio Expansion and then Director for BD&L, responsible for Europe, Canada, Japan, Australia, Korea and Middle East. He has built country portfolios at global and local levels to support Abbott´s ambitious growth plans. Before joining STADA, Yann worked as the Managing Director of Exeltis (INSUD PHARMA). In this role he led 3,900 employees. He put the company on a good growth track with a clearly defined strategy, commercialization focus and a strong pipeline.  

Yann Brun will fully contribute to strengthening STADA´s global strategy: “Superior Growth through pipeline acceleration” is one key strategic pillar. „I am excited to be joining STADA and becoming part of an agile, growing company. STADA has over the last 2 years done a lot of promising deals to strengthen its specialty and consumer healthcare portfolio, and also has an extensive generics development pipeline of its own. I will build on this and further accelerate global partnerships based on STADA´s purpose of „Caring for People´s Health as a trusted partner“, commented Yann Brun.

 

About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two-pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2019, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. As of December 31, 2019, STADA employed 11,100 people worldwide.

Additional information for journalists
STADA Arzneimittel AG
Media Relations
Stadastrasse 2-18
61118 Bad Vilbel - Germany
Phone: +49 (0) 6101 603-165
Fax: +49 (0) 6101 603-215
E-Mail: press@stada.de

Additional information for capital market participants
STADA Arzneimittel AG
Investor & Creditor Relations
Stadastrasse 2-18
61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-4689
Fax: +49 (0) 6101 603-215
E-mail: ir@stada.de